Cargando…

Low-dose decitabine enhances the effect of PD-1 blockade in colorectal cancer with microsatellite stability by re-modulating the tumor microenvironment

PD-1 blockade has demonstrated impressive clinical outcomes in colorectal cancers that have high microsatellite instability. However, the therapeutic efficacy for patients with tumors with low microsatellite instability or stable microsatellites needs further improvement. Here, we have demonstrated...

Descripción completa

Detalles Bibliográficos
Autores principales:	Yu, Ganjun, Wu, Yanfeng, Wang, Wenying, Xu, Jia, Lv, Xiaoping, Cao, Xuetao, Wan, Tao
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2018
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6461874/ https://www.ncbi.nlm.nih.gov/pubmed/29622799 http://dx.doi.org/10.1038/s41423-018-0026-y

Ejemplares similares

Synergistic Therapeutic Effects of Low Dose Decitabine and NY-ESO-1 Specific TCR-T Cells for the Colorectal Cancer With Microsatellite Stability
por: Yu, Ganjun, et al.
Publicado: (2022)

Gegen Qinlian decoction enhances the effect of PD-1 blockade in colorectal cancer with microsatellite stability by remodelling the gut microbiota and the tumour microenvironment
por: Lv, Ji, et al.
Publicado: (2019)

Decitabine Augments Chemotherapy-Induced PD-L1 Upregulation for PD-L1 Blockade in Colorectal Cancer
por: Huang, Kevin Chih-Yang, et al.
Publicado: (2020)

PD-1 blockade in neoadjuvant setting of DNA mismatch repair-deficient/microsatellite instability-high colorectal cancer
por: Liu, Ding-Xin, et al.
Publicado: (2020)

The degree of microsatellite instability predicts response to PD-1 blockade immunotherapy in mismatch repair-deficient/microsatellite instability-high colorectal cancers
por: Wang, Qiao-Xuan, et al.
Publicado: (2021)

Low-dose immunogenic chemotherapeutics promotes immune checkpoint blockade in microsatellite stability colon cancer
por: Fang, Yuhang, et al.
Publicado: (2022)

Metastatic Colorectal Cancer Patient With Microsatellite Stability and BRAF(V600E) Mutation Showed a Complete Metabolic Response to PD-1 Blockade and Bevacizumab: A Case Report
por: Fang, Chongkai, et al.
Publicado: (2021)

Selecting suitable chemotherapies for PD-1/PD-L1 blockade to optimize the tumor immune microenvironment
por: Koyama, Shohei, et al.
Publicado: (2018)

Therapeutic efficacy of combined blockade of CTLA-4 +/- PD-L1 +/- IDO is associated with re-activation of T cells directly within the tumor microenvironment
por: Spranger, Stefani, et al.
Publicado: (2013)

Combination Immunotherapies to Overcome Intrinsic Resistance to Checkpoint Blockade in Microsatellite Stable Colorectal Cancer
por: Kim, Chang Woo, et al.
Publicado: (2021)

Novel prodrugs of decitabine with greater metabolic stability and less toxicity
por: Hattori, Naoko, et al.
Publicado: (2019)

Low-Dose Decitabine Inhibits Cytotoxic T Lymphocytes-Mediated Platelet Destruction via Modulating PD-1 Methylation in Immune Thrombocytopenia
por: Han, Panpan, et al.
Publicado: (2021)

Single-cell sequencing reveals the immune microenvironment landscape related to anti-PD-1 resistance in metastatic colorectal cancer with high microsatellite instability
por: Wu, Tao, et al.
Publicado: (2023)

Remodeling Chondroitin-6-Sulfate–Mediated Immune Exclusion Enhances Anti–PD-1 Response in Colorectal Cancer with Microsatellite Stability
por: Wu, Qijing, et al.
Publicado: (2022)

Ambra1 modulates the tumor immune microenvironment and response to PD-1 blockade in melanoma
por: Frias, Alex, et al.
Publicado: (2023)

Acquired resistance to decitabine and cross-resistance to gemcitabine during the long-term treatment of human HCT116 colorectal cancer cells with decitabine
por: HOSOKAWA, MIKA, et al.
Publicado: (2015)

Characterisation of PD-L1-positive subsets of microsatellite-unstable colorectal cancers
por: Kim, Jung Ho, et al.
Publicado: (2016)

Treatment with decitabine induces the expression of stemness markers, PD-L1 and NY-ESO-1 in colorectal cancer: potential for combined chemoimmunotherapy
por: Taib, Nassiba, et al.
Publicado: (2023)

Decitabine bioproduction using a biocatalyst with improved stability by adding nanocomposites
por: Méndez, Mariana B., et al.
Publicado: (2020)

Epigenetic Anti‐Cancer Treatment With a Stabilized Carbocyclic Decitabine Analogue
por: Traube, Franziska R., et al.
Publicado: (2022)

Expression of PD1/PDL1 in gastric cancer at different microsatellite status and its correlation with infiltrating immune cells in the tumor microenvironment
por: Wang, Yan-li, et al.
Publicado: (2021)

Outcomes and a prognostic classifier in patients with microsatellite instability-high metastatic gastric cancer receiving PD-1 blockade
por: Randon, Giovanni, et al.
Publicado: (2023)

Effective treatment of low-dose decitabine in myelodysplastic syndrome/myeloproliferative neoplasms
por: Ye, Xingnong, et al.
Publicado: (2017)

Augmenting chemotherapy with low-dose decitabine through an immune-independent mechanism
por: Gutierrez, Wade R., et al.
Publicado: (2022)

Cyclin G2 reverses immunosuppressive tumor microenvironment and potentiates PD-1 blockade in glioma
por: Li, Sen, et al.
Publicado: (2021)

Genomic features and tumor immune microenvironment alteration in NSCLC treated with neoadjuvant PD-1 blockade
por: Wang, Shuhang, et al.
Publicado: (2022)

Treg-Dominant Tumor Microenvironment Is Responsible for Hyperprogressive Disease after PD-1 Blockade Therapy
por: Wakiyama, Hiroaki, et al.
Publicado: (2022)

Di-O-lauroyl-decitabine-lipid nanocapsules: toward extending decitabine activity
por: Briot, Thomas, et al.
Publicado: (2019)

Low-Dose Decitabine-Based Chemoimmunotherapy for Patients with Refractory Advanced Solid Tumors: A Phase I/II Report
por: Fan, Hui, et al.
Publicado: (2014)

Targeting immune cell types of tumor microenvironment to overcome resistance to PD-1/PD-L1 blockade in lung cancer
por: Wang, Man, et al.
Publicado: (2023)

Are High Levels of Microsatellite Instability and Microsatellite Stability Identical in DNA Mismatch Repair-Deficient Colorectal Cancer Patients?
por: Qiu, Yan-Yu, et al.
Publicado: (2023)

Microsatellite stability and mismatch repair proficiency in nasopharyngeal carcinoma may not predict programmed death-1 blockade resistance
por: Liao, Xiyi, et al.
Publicado: (2017)

Fusobacterium nucleatum enhances the efficacy of PD-L1 blockade in colorectal cancer
por: Gao, Yaohui, et al.
Publicado: (2021)

The Contrasting Delayed Effects of Transient Exposure of Colorectal Cancer Cells to Decitabine or Azacitidine
por: Pawlak, Alicja, et al.
Publicado: (2022)

Crosstalk Between PD-1/PD-L1 Blockade and Its Combinatorial Therapies in Tumor Immune Microenvironment: A Focus on HNSCC
por: Lin, Weimin, et al.
Publicado: (2018)

Clonal replacement of novel T cells: a new phenomenon in the tumor microenvironment following PD-1 blockade
por: Li, Xue, et al.
Publicado: (2019)

Single-cell transcriptomics reveals the effect of PD-L1/TGF-β blockade on the tumor microenvironment
por: Lim, Yoong Wearn, et al.
Publicado: (2021)

Relationship between microsatellite status and immune microenvironment of colorectal cancer and its application to diagnosis and treatment
por: Bai, Junge, et al.
Publicado: (2021)

Decitabine in the treatment of myelodysplastic syndromes
por: Saba, Hussain I
Publicado: (2007)

Decitabine/Cedazuridine: First Approval
por: Dhillon, Sohita
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_b35k06a4f5roungq616bbr4blk